InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,548.59
(
-0.71%
)
US TECH 100
19,143.60
(
-0.66%
)
Dow Jones
40,768.77
(
-1.04%
)
Brent Oil
84.39
(
-0.12%
)
Bitcoin
63,549.87
(
-0.83%
)
Post# of 4974628
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

legacyinvestor

Send PM Follow Ignore
Followers 21
Posts 1120
Boards Moderated 0
Alias Born 08/25/2006

legacyinvestor

Re: None

Thursday, 06/21/2007 1:04:13 PM

Thursday, June 21, 2007 1:04:13 PM

Post# of 4974628
Huge COLY thought-

Lazard Capital Markets analyst Terence Flynn downgraded shares of the Wellesley, Mass.-based company to "Hold" from "Buy," and said he based most of his estimate of the company's value on the drug's success.

*******However, he noted that at least one PF-3512676 trial was not stopped Wednesday.

"The press release does not mention an ongoing Phase I trial of '676 and Ticilimumab for melanoma; therefore, it is unclear to us at this point if Pfizer plans to continue development of '676," he said.*******

hmmmmmmmm

.
He who loves money will not be satisfied with money, nor he who loves abundance with its income. This too is vanity.
-Eccl 5:10

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up